0.14 (-%)
As of Jun 03, 2024
Source:
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy.
Country | United States |
Headquarters | malvern, pennsylvania |
Phone Number | 610-725-1500 |
Industry | manufacturing |
CEO | J. Mel Sorensen, M.D. |
Website | www.clinicaltrials.gov |